loading
Precedente Chiudi:
$1.12
Aprire:
$1.12
Volume 24 ore:
7.28M
Relative Volume:
1.99
Capitalizzazione di mercato:
$264.04M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.5613
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
+8.18%
1M Prestazione:
-16.20%
6M Prestazione:
-45.16%
1 anno Prestazione:
-54.05%
Intervallo 1D:
Value
$1.11
$1.23
Intervallo di 1 settimana:
Value
$1.03
$1.23
Portata 52W:
Value
$0.8621
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
Nome
Allogene Therapeutics Inc
Name
Telefono
(650) 457-2700
Name
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
361
Name
Cinguettio
@AllogeneTx
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
ALLO's Discussions on Twitter

Confronta ALLO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.19 241.85M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-14 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 Aggiornamento Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 Ripresa Oppenheimer Outperform
2024-05-31 Iniziato Piper Sandler Overweight
2024-01-05 Downgrade Guggenheim Buy → Neutral
2024-01-05 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 Iniziato Citigroup Buy
2023-06-26 Ripresa Oppenheimer Outperform
2023-03-21 Iniziato Bernstein Mkt Perform
2023-01-24 Aggiornamento JP Morgan Neutral → Overweight
2023-01-06 Aggiornamento Robert W. Baird Neutral → Outperform
2022-12-12 Downgrade BofA Securities Buy → Underperform
2022-08-10 Downgrade Raymond James Outperform → Mkt Perform
2022-07-15 Aggiornamento Goldman Neutral → Buy
2022-06-03 Iniziato Robert W. Baird Neutral
2022-02-28 Reiterato B. Riley Securities Buy
2021-10-20 Iniziato Cowen Outperform
2021-10-08 Downgrade Goldman Buy → Neutral
2021-10-08 Downgrade Stifel Buy → Hold
2021-09-23 Aggiornamento Raymond James Mkt Perform → Outperform
2021-06-21 Ripresa Jefferies Buy
2021-05-20 Aggiornamento Truist Hold → Buy
2021-05-14 Iniziato B. Riley Securities Buy
2021-01-26 Aggiornamento Stifel Hold → Buy
2020-12-10 Ripresa H.C. Wainwright Buy
2020-11-24 Iniziato BofA Securities Buy
2020-10-23 Iniziato RBC Capital Mkts Outperform
2020-06-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-29 Reiterato H.C. Wainwright Buy
2020-05-19 Aggiornamento ROTH Capital Neutral → Buy
2020-05-15 Aggiornamento Guggenheim Neutral → Buy
2020-05-14 Reiterato H.C. Wainwright Buy
2020-05-14 Downgrade SunTrust Buy → Hold
2020-04-13 Iniziato SunTrust Buy
2020-03-13 Iniziato H.C. Wainwright Buy
2020-03-05 Iniziato Stifel Hold
2020-02-24 Iniziato Berenberg Hold
2019-12-18 Iniziato JMP Securities Mkt Outperform
2019-11-04 Iniziato Canaccord Genuity Buy
2019-08-09 Iniziato BTIG Research Buy
2019-06-05 Iniziato ROTH Capital Neutral
2019-05-31 Iniziato Guggenheim Neutral
2019-05-23 Iniziato Stifel Hold
2019-03-29 Iniziato Piper Jaffray Overweight
Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

pulisher
Aug 19, 2025

Allogene Q2 Cash Tops $300 Million - AOL.com

Aug 19, 2025
pulisher
Aug 19, 2025

Allogene Therapeutics Inc. Facing Inflection Point in Trend AnalysisPrice Action & Daily Entry Point Alerts - beatles.ru

Aug 19, 2025
pulisher
Aug 19, 2025

Real time pattern detection on Allogene Therapeutics Inc. stockJuly 2025 Short Interest & Low Risk Growth Stock Ideas - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Ranking Allogene Therapeutics Inc. among high performing stocks via toolsTrade Volume Summary & Weekly Top Gainers Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Will Allogene Therapeutics Inc. outperform the marketJuly 2025 Spike Watch & Reliable Price Action Trade Plans - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Full technical analysis of Allogene Therapeutics Inc. stockWeekly Gains Summary & Safe Capital Allocation Plans - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

How to track smart money flows in Allogene Therapeutics Inc.Portfolio Profit Report & Community Supported Trade Ideas - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

What machine learning models say about Allogene Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Backtesting results for Allogene Therapeutics Inc. trading strategiesBreakout Watch & Advanced Swing Trade Entry Plans - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

What recovery options are there for Allogene Therapeutics Inc.Weekly Market Summary & Safe Capital Allocation Plans - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Published on: 2025-08-19 03:10:25 - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Can swing trading help recover from Allogene Therapeutics Inc. losses2025 Macro Impact & Low Risk Entry Point Tips - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Signal strength of Allogene Therapeutics Inc. stock in tech scannersJuly 2025 Chart Watch & Safe Entry Point Identification - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

Will Allogene Therapeutics Inc. benefit from macro trendsJuly 2025 Levels & Weekly High Momentum Picks - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Allogene Therapeutics Inc. stock chart pattern explainedBuy Signal & Breakout Confirmation Trade Signals - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Understanding Allogene Therapeutics Inc.’s price movementTrade Analysis Report & Verified Swing Trading Watchlist - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Allogene Therapeutics Q2 2025 Earnings Preview: Revenue Expectations Flat, Earnings Estimates Rise - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha

Aug 14, 2025
pulisher
Aug 14, 2025

Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - 富途牛牛

Aug 14, 2025
pulisher
Aug 14, 2025

Allogene's Q2 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com

Aug 14, 2025
pulisher
Aug 14, 2025

Allogene Therapeutics shares rise 1.92% premarket after reporting better-than-expected Q2 earnings. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline By Investing.com - Investing.com South Africa

Aug 14, 2025
pulisher
Aug 14, 2025

Allogene Therapeutics: Q2 Earnings Snapshot - Greenwich Time

Aug 14, 2025
pulisher
Aug 14, 2025

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

Aug 14, 2025
pulisher
Aug 14, 2025

Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛

Aug 14, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics Advances in CAR T Cell Therapy - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics Q2 2025 Earnings: A Strategic Leap in Cell Therapy Commercialization - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Transcript : Allogene Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene's Strategic Milestone Progress in 2026 and Its Implications for CAR T Leadership - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene Narrows Loss in Fiscal Q2 - Nasdaq

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times

Aug 13, 2025
pulisher
Aug 13, 2025

Allogene's CAR T Trials Show Promise in Cancer and Autoimmune Disease, $302M Cash Position - Stock Titan

Aug 13, 2025
pulisher
Aug 12, 2025

Allogene Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat

Aug 12, 2025
pulisher
Aug 12, 2025

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Aug 12, 2025
pulisher
Aug 11, 2025

Allogene Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView

Aug 11, 2025
pulisher
Aug 09, 2025

Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser

Aug 09, 2025

Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Capitalizzazione:     |  Volume (24 ore):